{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["8"],"submitter":["Tessoulin B"],"pubmed_abstract":["BCL2-family proteins have a central role in the mitochondrial apoptosis machinery and their expression is known to be deregulated in many cancer types. Effort in the development of small molecules that selectively target anti-apoptotic members of this family i.e., Bcl-2, Bcl-xL, Mcl-1 recently opened novel therapeutic opportunities. Among these apoptosis-inducing agents, BH3-mimetics (i.e., venetoclax) led to promising preclinical and clinical activity in B cell malignancies. However, several mechanisms of intrinsic or acquired resistance have been described <i>ex vivo</i> therefore predictive markers of response as well as mechanism-based combinations have to be designed. In the present study, we analyzed the expression of the BCL2-family genes across 10 mature B cell malignancies through"],"journal":["Frontiers in oncology"],"pagination":["645"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC6330761"],"repository":["biostudies-literature"],"pubmed_title":["BCL2-Family Dysregulation in B-Cell Malignancies: From Gene Expression Regulation to a Targeted Therapy Biomarker."],"pmcid":["PMC6330761"],"pubmed_authors":["Papin A","Gomez-Bougie P","Pellat-Deceunynck C","Tessoulin B","Bellanger C","Amiot M","Chiron D"],"additional_accession":[]},"is_claimable":false,"name":"BCL2-Family Dysregulation in B-Cell Malignancies: From Gene Expression Regulation to a Targeted Therapy Biomarker.","description":"BCL2-family proteins have a central role in the mitochondrial apoptosis machinery and their expression is known to be deregulated in many cancer types. Effort in the development of small molecules that selectively target anti-apoptotic members of this family i.e., Bcl-2, Bcl-xL, Mcl-1 recently opened novel therapeutic opportunities. Among these apoptosis-inducing agents, BH3-mimetics (i.e., venetoclax) led to promising preclinical and clinical activity in B cell malignancies. However, several mechanisms of intrinsic or acquired resistance have been described <i>ex vivo</i> therefore predictive markers of response as well as mechanism-based combinations have to be designed. In the present study, we analyzed the expression of the BCL2-family genes across 10 mature B cell malignancies through","dates":{"release":"2018-01-01T00:00:00Z","publication":"2018","modification":"2025-04-18T15:15:26.296Z","creation":"2019-03-26T22:38:42Z"},"accession":"S-EPMC6330761","cross_references":{"pubmed":["30666297"],"doi":["10.3389/fonc.2018.00645"]}}